PSMA-based Theranostics in Advanced Non–small Cell Lung Cancer
Prostate-specific membrane antigen (PSMA) overexpression on prostate cancer cells finally led to the FDA approval of the therapeutic use of 177 Lu-PSMA-617 in metastatic castrate-resistant prostate cancer. However, PSMA is also expressed in the neovasculature of other solid tumors, such as lung and renal cancer, making the theranostic potential of 177 Lu-PSMA-617 worth exploring in this setting. Here is such a case of an 83-year-old man with advanced non-small cell lung cancer where the theranostic potential of 177 Lu-PSMA-617 was explored using dosimetric analysis.
Authors
- Anupriya Anwariya
- Navneet Singh (ORCID: https://orcid.org/0000-0002-8389-0701)
- Komalpreet Kaur (ORCID: https://orcid.org/0000-0002-6146-7769)
- Swayamjeet Satapathy (ORCID: https://orcid.org/0000-0001-5318-6644)
- Amanjit Bal (ORCID: https://orcid.org/0000-0002-1457-8589)
- Bhagwant Rai Mittal (ORCID: https://orcid.org/0000-0002-0016-5783)
- Ashwani Sood (ORCID: https://orcid.org/0000-0001-7228-0361)
- Piyush Aggarwal (ORCID: https://orcid.org/0000-0002-3067-3113)
- Harmandeep Singh (ORCID: https://orcid.org/0000-0003-3934-8031)
Institutions
- Pulmonary Associates (US)
- Post Graduate Institute of Medical Education and Research (IN)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1097/rlu.0000000000005816
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52